Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
"I know when to stop": sentinels and counterstrategies against drowsy driving in narcolepsy and idiopathic hypersomnia.
Sleep
December 2024
Sleep Clinic, Pitie-Salpetriere Hospital, DMU APPROCHES, APHP - Sorbonne University, Paris, France.
Study Objectives: To collect prodromal symptoms experienced by participants with narcolepsy and idiopathic hypersomnia (considered "hypersomnolence experts") prior to drowsy driving and counterstrategies used to maintain alertness.
Methods: Systematic, face-to-face interview (using a semi-structured questionnaire), including clinical measures, frequency of car accidents/near misses, and symptoms experienced before impending drowsy driving episodes and counterstrategies.
Results: Among 61 participants (32 with narcolepsy, 29 with idiopathic hypersomnia; 56 drivers), 61% of drivers had at least one lifetime accident/near miss.
Skin temperature as a predictor of on-the-road driving performance in people with central disorders of hypersomnolence.
J Sleep Res
May 2024
Stichting Epilepsie Instellingen Nederland (SEIN), Sleep-Wake Centre, Heemstede, The Netherlands.
Excessive daytime sleepiness is the core symptom of central disorders of hypersomnolence (CDH) and can directly impair driving performance. Sleepiness is reflected in relative alterations in distal and proximal skin temperature. Therefore, we examined the predictive value of skin temperature on driving performance.
View Article and Find Full Text PDFThe Bordeaux Sleepiness Scale (BOSS): a new questionnaire to measure sleep-related driving risk.
J Clin Sleep Med
May 2023
Sleep, Addiction and Neuropsychiatry, University of Bordeaux, Bordeaux, France.
Study Objectives: Sleepiness is a well-known risk factor for traffic accidents. Our study presents a new questionnaire, the Bordeaux Sleepiness Scale (BOSS), specifically designed to evaluate sleep-related driving risk in patients with sleep disorders.
Methods: The BOSS was designed by gathering data on sociodemographics, sleepiness, driving items, and traffic accident exposure (kilometers driven) in the past year of 293 patients followed for sleep disorders at a French sleep clinic.
Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial.
Hum Psychopharmacol
January 2023
Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Objective: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving performance in participants with narcolepsy.
Methods: In this randomised, double-blind, placebo-controlled, crossover study, driving performance during a 1 h on-road driving test was assessed at 2 and 6 h post-dose following 7 days of treatment with solriamfetol (150 mg/day for 3 days, followed by 300 mg/day for 4 days) or placebo. The primary endpoint was standard deviation of lateral position (SDLP) at 2 h post-dose.
On-the-road driving performance of patients with central disorders of hypersomnolence.
Traffic Inj Prev
June 2021
Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.
Introduction: Excessive Daytime Sleepiness is a core symptom of narcolepsy and idiopathic hypersomnia, which impairs driving performance. Adequate treatment improves daytime alertness, but it is unclear whether driving performance completely normalizes. This study compares driving performance of patients with narcolepsy and idiopathic hypersomnia receiving treatment to that of healthy controls.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!